Cargando…
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
The serum expression of a novel tumour marker, CA 242, defined by monoclonal antibody C 242, was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA. CA 242 is a carbohydrate closely related, but not identical, to CA 19-9 and CA 50. The overall sensi...
Autores principales: | Haglund, C., Lundin, J., Kuusela, P., Roberts, P. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033366/ https://www.ncbi.nlm.nih.gov/pubmed/8080735 |
Ejemplares similares
-
Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
por: Kuusela, P., et al.
Publicado: (1991) -
Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
por: Haglund, C., et al.
Publicado: (1989) -
Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995) -
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.
por: Lundin, J., et al.
Publicado: (1994) -
Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
por: Kuusela, P., et al.
Publicado: (1987)